Anti-B cell therapy with rituximab as induction therapy in renal transplantation

There is no fulltext present in this item.

Title:	Anti-B cell therapy with rituximab as induction therapy in renal transplantation
Author(s):	Joosten, I. ; Baas, M.C. ; Kamburova, E.G. ; Hoogen, M.W.F. van den ; Koenen, H.J.P.M. ; Hilbrands, L.B.
Publication year:	2014
Source:	Transplant Immunology, vol. 31, iss. 4, (2014), pp. 207-209
ISSN:	0966-3274
DOI:	https://doi.org/10.1016/j.trim.2014.09.011
Publication type:	Article / Letter to editor
Please use this identifier to cite or link to this item : https://hdl.handle.net/2066/136415
Display more details
Subject:	Radboudumc 11: Renal disorders RIHS: Radboud Institute for Health Sciences Radboudumc 5: Inflammatory diseases RIMLS: Radboud Institute for Molecular Life Sciences
Organization:	Paediatrics - OUD tm 2017 Laboratory Medicine Nephrology
Journal title:	Transplant Immunology
Volume:	vol. 31
Issue:	iss. 4
Page start:	p. 207
Page end:	p. 209
Abstract:	Traditionally, antirejection therapy in organ transplantation has mainly been directed at T cells. During recent years, the role of B cells in acute rejection has attracted more attention. In the Radboud University Medical Center (Nijmegen, The Netherlands) we performed a randomized, placebo controlled study to assess the efficacy and safety of rituximab as induction therapy after renal transplantation. In parallel we investigated the effects of rituximab on the numbers and function of B and T cells. An overview of the results, which have largely been published in peer reviewed papers, is presented below.